ELSEVIER

Clinica Chimica Acta 253 (1996) 185–186

Author index

Volume 253 (1996)

Apperley, J., see Nawawi, H. **252**, 61
Archbold, G.P.R., see McDonnell, M.G. **252**, 117

Bergmann, S., see Kopprasch, S. **252**, 145
Bird, G.L.A., see Thorburn, D. **252**, 171
Bladon, P.T., T.E. Rowlands, J.A. Whittaker, R.E. Oakey, Serum cortisol binding capacity measured with Concanavalin A-Sepharose in patients with a recent inflammatory response **253**, 9

Cederblad, G., see Shenkin, A. **252**, S1
Contois, J.H., C.J. Lammi-Keefe, S. Vogel, J.R. McNamara, P.W.F. Wilson, T. Massov, E.J. Schaefer, Plasma lipoprotein(a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay **253**, 21

Daenena, P., see Mannaert, E. **252**, 103

Elia, M., see Shenkin, A. **252**, S1

Fournier, B., see Regis-Bailly, A. **252**, 127
Fujimura, Y., M. Kawamura, A simple micromethod for determining urea cycle intermediates in blood: ornithine, arginine and argininosuccinic acid **253**, 1
Fukao, H., see Hagiya, Y. **252**, 37

Girgis, S., see Nawawi, H. **252**, 51
Graessler, J., see Kopprasch, S. **252**, 145
Gueguen, R., see Regis-Bailly, A. **252**, 127

Hagiya, Y., H. Fukao, S. Ueshima, K. Okada, H. Inufusa, H. Kamiishi, O. Matsuo, Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line **253**, 37
Hartikainen, A-L., see Rutanen, E-M. **252**, 91
Hinkula, M.K., see Rutanen, E-M. **252**, 91

Imafuku, Y., T. Nagai, H. Yoshida, The effect of toilet sanitizers and detergents on immunological occult blood tests **253**, 51
Inufusa, H., see Hagiya, Y. **252**, 37
Isaksson, B., see Shenkin, A. **252**, S1

Jain, S.K., M. Palmer, Effect of glucose-6-phosphate dehydrogenase deficiency on reduced and oxidized glutathione and lipid peroxide levels in the blood of African-Americans **253**, 181

Kamiishi, H., see Hagiya, Y. **252**, 37
Kärkkäinen, T.H., see Rutanen, E-M. **252**, 91
Kawamura, M., see Fujimura, Y. **252**, 1
Kohl, M., see Kopprasch, S. **252**, 145
Kopprasch, S., J. Graessler, M. Kohl, S. Bergmann, H.-E. Schröder, Comparison of circulating phagocyte oxidative activity measured by chemiluminescence in whole blood and isolated polymorphonuclear leukocytes **253**, 145
Koskinen, L.K., Specificity of hemoglobin A_{1c} measurement by cation exchange liquid chromatography. Evaluation of a Mono S column method **253**, 159
Krähenbühl, S., T. Schäfer, U. Wiesmann, Determination of the activities of the enzyme

0098-8981/96/$15.00 © 1996 Elsevier Science B.V. All rights reserved

complexes of the electron transport chain in human fibroblasts **253**, 79

Lammi-Keefe, C.J., see Contois, J.H. **252**, 21
Lehtovirta, J., see Rutanen, E-M. **252**, 91

MacSween, R.N.M., see Thorburn, D. **252**, 171
Mannaert, E., J. Tytgat, P. Daenens, Development of a stereospecific radioimmunoassay for the analysis of zopiclone and metabolites in urine **252**, 103
Massov, T., see Contois, J.H. **252**, 21
Matsuo, O., see Hagiya, Y. **252**, 37
McDonnell, M.G., G.P.R. ArchboldPlasma ubiquinol/cholesterol ratios in patients with hyperlipidaemia, those with diabetes mellitus and in patients requiring dialysis **252**, 117
McNamara, J.R., see Contois, J.H. **252**, 21
Mills, P.R., see Thorburn, D. **252**, 171

Nagai, T., see Imafuku, Y. **252**, 51
Nawawi, H., D. Samson, J. Apperley, S. Girgis, Biochemical bone markers in patients with multiple myeloma **253**, 61

Oakey, R.E., see Bladon, P.T. **252**, 9
Okada, K., see Hagiya, Y. **252**, 37

Palmer, M., see Jain, S.K. **252**, 181
Regis-Bailly, A., S. Visvikis, J. Steinmetz, B. Fournier, R. Gueguen, G. Siest, Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal **253**, 127
Rowlands, T.E., Bladon, P.T. **252**, 9
Rutanen, E-M., T.H. Kärkkäinen, J. Lehtovirta, J.T. Uotila, M.K. Hinkula, A-L. Hartikainen, Evaluation of a rapid strip test for insulin-like growth factor binding protein-1 in the diagnosis of ruptured fetal membranes **253**, 91

Wamson, D., see Nawawi, H. **252**, 61
Schaefer, E.J., see Contois, J.H. **252**, 37
Schäfer, T., see Krähenbühl, S. **252**, 79
Schröder, H.-E., see Kopprasch, S. **252**, 145
Shenkin, A., G. Cederblad, M. Elia, B. Isaksson, Laboratory assessment of protein-energy status **252**, S1
Siest, G., see Regis-Bailly, A. **252**, 127
Spence, E., see Thorburn, D. **252**, 171
Steinmetz, J., see Regis-Bailly, A. **252**, 127

Thorburn, D., G.L.A. Bird, E. Spence, R.N.M. MacSween, P.R. Mills, α-Glutathione *S*-transferase levels in chronic hepatitis C infection and the effect of α-interferon therapy **253**, 171
Tytgat, J., see Mannaert, E. **252**, 103

Ueshima, S., see Hagiya, Y. **252**, 37
Uotila, J.T., see Rutanen, E-M. **252**, 91

Visvikis, S., see Regis-Bailly, A. **252**, 127
Vogel, S., see Contois, J.H. **252**, 21

Whittaker, J.A., see Bladon, P.T. **252**, 9
Wiesmann, U., see Krähenbühl, S. **252**, 79
Wilson, P.W.F., see Contois, J.H. **252**, 21

Yoshida, H., see Imafuku, Y. **252**, 51

ELSEVIER

Clinica Chimica Acta 253 (1996) 187–189

Subject index

Volume 253 (1996)

Alanine aminotransferase; α-Glutathione *S*-transferase; Hepatitis C; α-Interferon **253**, 171

Amniotic fluid; PROM; Insulin-like growth factor binding protein-1 (IGFBP-1); Preterm delivery **253**, 91

Apo B; Lipid metabolism; Postprandial lipaemia; Genetic polymorphisms; Apo E **253**, 127

Apo E; Lipid metabolism; Postprandial lipaemia; Genetic polymorphisms; Apo B; **253**, 127

Available cortisol; Inflammation; Corticosteroid binding globulin; Septic shock; Ligand binding **253**, 9

Biochemical bone markers; Multiple myeloma **253**, 61

Cation exchange liquid chromatography; Hemoglobin A, glycosylated **253**, 159

Chemiluminescence; Whole blood; Leukocytes; Reactive Oxygen species; Serum lipids; Uric acid **253**, 145

Cholesterol; Lipoprotein(a); Lipids; Lipoproteins; Coronary heart disease; Epidemiology **253**, 21

Clinical chemistry tests; Nutritional intake; Protein-energy malnutrition; Undernutrition; **253**, S1

Coronary heart disease; Lipoprotein(a); Lipids; Lipoproteins; Cholesterol; Epidemiology **253**, 2 1

Corticosteroid binding globulin; Inflammation; Available cortisol; Septic shock; Ligand binding **253**, 9

Cyclopyrrolone hypnotic; Radioimmunoassay; Stereoselectivity; Zopiclone **253**, 103

Detergent; Fecal occult blood test; Hemoglobin; Toilet sanitizer **253**, 51

Diabetics; Ubiquinol; Oxidative stress; Haemodialysis; CAPD **253**, 117

Electron transport chain; Fibroblast; Mitochondria; Enzyme complexes **253**, 79

Enzymatic method; Urea cycle diseases; Urea cycle intermediates (Ornithine-Arginine-Argininosuccinic acid); Microfluorometric method of NADH; Microplate method **253**, 1

Enzyme complexes; Electron transport chain; Fibroblast; Mitochondria **253**, 79

Epidemiology; Lipoprotein(a); Lipids; Lipoproteins; Cholesterol; Coronary heart disease **253**, 21

Erythrocytes; G6PD deficiency; GSH; Lipid peroxidation **253**, 181

Extracellular matrix; Urokinase-type plasminogen activator; Highly metastatic cell line;

0098-8981/96/$15.00 © 1996 Elsevier Science B.V. All rights reserved

High performance liquid chromatography **253**, 37

Fecal occult blood test; Hemoglobin; Detergent; Toilet sanitizer **253**, 51

Genetic polymorphisms; Lipid metabolism; Postprandial lipaemia; Apo B; Apo E **253**, 127

α-Glutathione *S*-transferase; Alanine aminotransferase; Hepatitis C; α-Interferon **253**, 171

G6PD deficiency; GSH; Erythrocytes; Lipid peroxidation **253**, 181

Haemodialysis; Ubiquinol; Oxidative stress; Diabetics; CAPD **253**, 117

Hemoglobin; Fecal occult blood test; Detergent; Toilet sanitizer **253**, 51

Hemoglobin A, glycosylated; Cation exchange liquid chromatography **253**, 159

Hepatitis C; Alanine aminotransferase; α-Glutathione *S*-transferase; α-Interferon **253**, 171

Highly metastatic cell line; Urokinase-type plasminogen activator; Extracellular matrix; High performance liquid chromatography **253**, 37

High performance liquid chromatography; Urokinase-type plasminogen activator; Extracellular matrix; Highly metastatic cell line **253**, 37

Inflammation; Corticosteroid binding globulin; Available cortisol; Septic shock; Ligand binding **253**, 9

Insulin-like growth factor binding protein-1 (IGFBP-1); PROM; Amniotic fluid; Preterm delivery **253**, 91

α-Interferon; Alanine aminotransferase; α-Glutathione *S*-transferase; Hepatitis C **253**, 171

Leukocytes; Chemiluminescence; Whole blood; Reactive Oxygen species; Serum lipids; Uric acid **253**, 145

Ligand binding; Inflammation; Corticosteroid binding globulin; Available cortisol; Septic shock **253**, 9

Lipids; Lipoprotein(a); Lipoproteins; Cholesterol; Coronary heart disease; Epidemiology **253**, 21

Lipoproteins; Lipoprotein(a); Lipids; Cholesterol; Coronary heart disease; Epidemiology **253**, 21

Lipoprotein(a); Lipids; Lipoproteins; Cholesterol; Coronary heart disease; Epidemiology **253**, 21

Lipid metabolism; Postprandial lipaemia; Genetic polymorphisms; Apo B; Apo E **253**, 127

Lipid peroxidation; G6PD deficiency; GSH; Erythrocytes **253**, 181

Microfluorometric method of NADH; Urea cycle diseases; Urea cycle intermediates (Ornithine-Arginine-Argininosuccinic acid); Enzymatic method; Microplate method **253**, 1

Microplate method; Urea cycle diseases; Urea cycle intermediates (Ornithine-Arginine-Argininosuccinic acid); Microfluorometric method of NADH; Enzymatic method **253**, 1

Mitochondria; Electron transport chain; Fibroblast; Enzyme complexes **253**, 79

Multiple myeloma; Biochemical bone markers **253**, 61

Nutritional intake; Protein-energy malnutrition; Undernutrition; Clinical chemistry tests **253**, S1

Oxidative stress; Ubiquinol; Diabetics; Haemodialysis; CAPD **253**, 117

Postprandial lipaemia; Lipid metabolism; Genetic polymorphisms; Apo B; Apo E **253**, 127

Preterm delivery; PROM; Amniotic fluid; Insulin-like growth factor binding protein-1 (IGFBP-1) **253**, 91

PROM; Amniotic fluid; Insulin-like growth factor binding protein-1 (IGFBP-1); Preterm delivery **253**, 91

Protein-energy malnutrition; Nutritional intake; Undernutrition; Clinical chemistry tests **253**, S1

Radioimmunoassay; Stereoselectivity; Cyclopyrrolone hypnotic; Zopiclone **253**, 103

Reactive oxygen species; Chemiluminescence; Whole blood; Leukocytes; Serum lipids; Uric acid **253**, 145

Septic shock; Inflammation; Corticosteroid binding globulin; Available cortisol; Ligand binding **253**, 9

Serum lipids; Chemiluminescence; Whole blood; Leukocytes; Reactive Oxygen species; Uric acid **253**, 145

Stereoselectivity; Radioimmunoassay; Cyclopyrrolone hypnotic; Zopiclone **253**, 103

Toilet sanitizer; Fecal occult blood test; Hemoglobin; Detergent **253**, 51

Ubiquinol; Oxidative stress; Diabetics; Haemodialysis; CAPD **253**, 117

Undernutrition; Nutritional intake; Protein-energy malnutrition; Clinical chemistry tests **253**, S1

Urea cycle diseases; Urea cycle intermediates (Ornithine-Arginine-Argininosuccinic acid); Microfluorometric method of NADH; Enzymatic method; Microplate method **253**, 1

Urea cycle intermediates (Ornithine-Arginine-Argininosuccinic acid); Urea cycle diseases; Microfluorometric method of NADH; Enzymatic method; Microplate method **253**, 1

Uric acid; Chemiluminescence; Whole blood; Leukocytes; Reactive Oxygen species; Serum lipids **253**, 145

Urokinase-type plasminogen activator; Extracellular matrix; Highly metastatic cell line; High performance liquid chromatography **253**, 37

Whole blood; Chemiluminescence; Leukocytes; Reactive Oxygen species; Serum lipids; Uric acid **253**, 145

Zopiclone; Radioimmunoassay; Stereoselectivity; Cyclopyrrolone hypnotic **253**, 103